×

News publications and other organizations are encouraged to reuse Direct Relief-published content for free under a Creative Commons License (Attribution-Non-Commercial-No Derivatives 4.0 International), given the republisher complies with the requirements identified below.

When republishing:

  • Include a byline with the reporter’s name and Direct Relief in the following format: "Author Name, Direct Relief." If attribution in that format is not possible, include the following language at the top of the story: "This story was originally published by Direct Relief."
  • If publishing online, please link to the original URL of the story.
  • Maintain any tagline at the bottom of the story.
  • With Direct Relief's permission, news publications can make changes such as localizing the content for a particular area, using a different headline, or shortening story text. To confirm edits are acceptable, please check with Direct Relief by clicking this link.
  • If new content is added to the original story — for example, a comment from a local official — a note with language to the effect of the following must be included: "Additional reporting by [reporter and organization]."
  • If republished stories are shared on social media, Direct Relief appreciates being tagged in the posts:
    • Twitter (@DirectRelief)
    • Facebook (@DirectRelief)
    • Instagram (@DirectRelief)

Republishing Images:

Unless stated otherwise, images shot by Direct Relief may be republished for non-commercial purposes with proper attribution, given the republisher complies with the requirements identified below.

  • Maintain correct caption information.
  • Credit the photographer and Direct Relief in the caption. For example: "First and Last Name / Direct Relief."
  • Do not digitally alter images.

Direct Relief often contracts with freelance photographers who usually, but not always, allow their work to be published by Direct Relief’s media partners. Contact Direct Relief for permission to use images in which Direct Relief is not credited in the caption by clicking here.

Other Requirements:

  • Do not state or imply that donations to any third-party organization support Direct Relief's work.
  • Republishers may not sell Direct Relief's content.
  • Direct Relief's work is prohibited from populating web pages designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
  • Advance permission is required to translate Direct Relief's stories into a language different from the original language of publication. To inquire, contact us here.
  • If Direct Relief requests a change to or removal of republished Direct Relief content from a site or on-air, the republisher must comply.

For any additional questions about republishing Direct Relief content, please email the team here.

Takeda

Partnerships for Humanity

Partnership Spotlight

Takeda has been strategic partner of Direct Relief for nearly a decade. and has donated more that 600,000 units of medicines which have been distributed to more than 60 countries including the United States and in response to over 20 major emergencies around the world.

In 2023, Takeda expanded it’s scope of oncology donation to include innovative therapies to further expand access to it’s topline for patients in low-to middle-income countries.

Takeda developed a strategic protocol to make unused clinical trial drugs used as baseline therapies available for donation to Direct Relief in support of providing standard medicines necessary for treatment regiments protocols in healthcare settings experiencing gaps in access.

Direct Relief is deeply grateful to Takeda for its leadership and commitment to providing charitable access to rare disease treatments to underserved patients around the world who would otherwise not be able to receive care. Private industry has an extraordinary ability to collaborate and a critical role to play for the public good, and Takeda is leading by example.


Bhupi Singh – Executive Vice President and Senior Advisor, Direct Relief

Rare Disease

In 2019, Takeda continued the charitable access program charitable access program for rare disease patient with LSD (GD, FD or MPSIII). The program provides lifelong access to therapies for over 300 patients in 17 countries which was initially started in 2013 with Shire.

Learn more

Ukraine

Takeda is a generous supporter of Direct Relief’s efforts to increase access to medicines in Ukraine via a consistent produce to give program of medicines for diabetes, epilepsy, kidney disease, ulcerative colitis, IBS, and other chronic conditions in which access to medicine is disrupted by the war

Learn more